
Perceptive's China upstart LianBio continues swinging deals, teaming up with lead Xontogeny biotech Landos in IBD
One of China’s biggest up-and-comers has a brand new partner, and it’s one whose backers are likely familiar with the other’s.
Perceptive’s LianBio has secured a collaboration with Landos Biopharma, the lead company in Chris Garabedian’s Xontogeny fund, to develop and market two programs in Greater China and other countries in the region, the biotechs announced Monday morning. In exchange, Landos is getting an upfront payment of $18 million, up to $200 million in milestones and royalties on sales in the licensed territories.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.